A Study of LY900014 in Participants With Type 1 Diabetes Mellitus
Type 1 Diabetes Mellitus

About this trial
This is an interventional basic science trial for Type 1 Diabetes Mellitus
Eligibility Criteria
Inclusion Criteria:
- Are male or female participants aged 6-64 with Type 1 Diabetes Mellitus (T1DM) for at least 1 year
- Have a glycated hemoglobin (HbA1c) less than (<)10.0 percent (%)
Exclusion Criteria:
- Receiving any oral or injectable medication intended for the treatment of diabetes mellitus other than insulins in the 12 months prior to screening
- More than one episode of severe hypoglycaemia in the last 6 months
- Presence of clinically significant hematologic, oncologic, renal, cardiac, hepatic, or gastrointestinal disease, proliferative retinopathy, uncontrolled celiac disease, uncontrolled hyperthyroidism or hypothyroidism, or adrenal insufficiency
- Have obvious clinical signs or symptoms of liver disease
- Have a history of renal impairment
Sites / Locations
- LMC Endocrinology Centres Ltd.
- Kinderkrankenhaus auf der Bult
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Experimental
Active Comparator
Experimental
Active Comparator
LY900014-Part A
Humalog (Insulin Lispro)-Part A
LY900014-Part B
Humalog (Insulin Lispro)-Part B
Participants received single 0.2 U/kg of body weight subcutaneous (SC) bolus injection of 100 U/mL LY900014.
Participants received single 0.2 U/kg of body weight SC bolus injection of 100 U/mL of Humalog.
Participants received single 0.2 U/kg of body weight SC bolus infusion of 100 U/mL LY900014 delivered using the continuous subcutaneous insulin infusion (CSII) pump.
Participants received single 0.2 U/kg of body weight SC bolus infusion of 100 U/mL Humalog delivered using the CSII pump.